worldwide offices | stay connected | contact | help | sitemap

 
 

 

 

 

Novartis Research and Development (R&D)

Novartis Research and Development (R&D)

Drug discovery and development process 

View interactive chart showing the steps of creating a new drug for Novartis, from target selection to registration and post-launch monitoring.

Novartis Institutes for BioMedical Research (NIBR)

Novartis Institutes for BioMedical Research (NIBR) 

The Novartis Institutes for BioMedical Research (NIBR) is a global research organization committed to discovering innovative medicines that treat disease and improve human health.

Pharmaceutical Development 

Novartis Pharmaceutical Development evaluates drug candidates and proves them to be high-quality therapies with superior value to patients.

Novartis Molecular Diagnostics 

Novartis Molecular Diagnostics is dedicated to developing companion and stand-alone diagnostic tests for patient-tailored treatments.

Corporate Research 

Novartis strives to address unmet medical needs by leveraging the specific scientific knowledge of four corporate research institutes: FMI, GNF, NITD and NVGH.

Animals & Research at Novartis 

Animal studies – undertaken with a commitment to the highest standards in animal welfare – are an essential part of the research and development of medical therapies and an integral part of the Novartis R&D operations.

Corporate Research locations

Research and Development locations 

Discover our research and development locations worldwide.

 

USD 7.5 billion 
During 2009, Novartis invested USD 7.5 billion in research and development. This is one of the highest figures in the industry relative to sales (17 percent).

79.5 million patients 
In 2009, our access-to-medicine programs, valued at USD 1.5 billion, reached 79.5 million patients.

Clinical pipeline

Clinical pipeline

Our product pipeline has 136 projects in various stages of clinical development.

Latest news

Careers

Our success depends on the creativity and performance of our associates.